Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
KalVista Pharmaceuticals (KALV)
NASDAQ:KALV
KalVista Pharmaceuticals (KALV) Stock Price & Analysis
280 Followers
KALV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.12 - $17.06
Previous Close$10.08
Volume191.46K
Average Volume (3M)246.07K
Market Cap
$344.43M
Enterprise Value$181.22M
Total Cash (Recent Filing)$171.69M
Total Debt (Recent Filing)$8.48M
Price to Earnings (P/E)-2.8
Beta0.84
Next Earnings
Jul 06, 2023EPS Estimate
-$0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.58
Shares Outstanding34,169,438
10 Day Avg. Volume224,842
30 Day Avg. Volume246,070
Standard Deviation0.28
R-Squared0.05
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.81
Forecast
1Y Price Target
$19.33Price Target Upside91.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
KalVista Pharmaceuticals News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KALV FAQ
What was KalVista Pharmaceuticals’s price range in the past 12 months?
KalVista Pharmaceuticals lowest stock price was $4.12 and its highest was $17.06 in the past 12 months.
What is KalVista Pharmaceuticals’s market cap?
Currently, no data Available
When is KalVista Pharmaceuticals’s upcoming earnings report date?
KalVista Pharmaceuticals’s upcoming earnings report date is Jul 06, 2023 which is in 33 days.
How were KalVista Pharmaceuticals’s earnings last quarter?
KalVista Pharmaceuticals released its earnings results on Mar 09, 2023. The company reported -$0.75 earnings per share for the quarter, beating the consensus estimate of -$0.985 by $0.235.
Is KalVista Pharmaceuticals overvalued?
According to Wall Street analysts KalVista Pharmaceuticals’s price is currently Undervalued.
Does KalVista Pharmaceuticals pay dividends?
KalVista Pharmaceuticals does not currently pay dividends.
What is KalVista Pharmaceuticals’s EPS estimate?
KalVista Pharmaceuticals’s EPS estimate is -$0.87.
How many shares outstanding does KalVista Pharmaceuticals have?
KalVista Pharmaceuticals has 34,169,437 shares outstanding.
What happened to KalVista Pharmaceuticals’s price movement after its last earnings report?
KalVista Pharmaceuticals reported an EPS of -$0.75 in its last earnings report, beating expectations of -$0.985. Following the earnings report the stock price went down -5.405%.
Which hedge fund is a major shareholder of KalVista Pharmaceuticals?
Among the largest hedge funds holding KalVista Pharmaceuticals’s share is Driehaus Capital Management LLC. It holds KalVista Pharmaceuticals’s shares valued at 8M.
---
KalVista Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.33 (91.77% Upside)
$19.33 (91.77% Upside)
Blogger Sentiment
Bullish
KALV Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 590.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.33%
12-Months-Change
Fundamentals
Return on Equity
-46.24%
Trailing 12-Months
Asset Growth
-9.59%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello and is headquartered in Cambridge, MA.
---
Top 5 ETFs holding KALV
Vanguard Total Stock Market ETF
$9.84M
iShares Russell 3000 ETF
$62.60K
Vanguard Russell 3000 ETF
$15.39K
Dimensional U.S. Equity ETF
$5.24K
iShares Core S&P Total U.S. Stock Market ETF
$175.50
Up to five ETFs with an Outperform Smart Score that hold KALV. The ETFs are listed according to market value of KALV within the ETF
---
---